Compare Vanguard Mega Cap Growth ETF (MGK) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Pfizer Inc — how do they compare? Vanguard Mega Cap Growth ETF trades at $94.43 (market cap $33.70B), while Pfizer Inc trades at $28.26 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 4.7× Vanguard Mega Cap Growth ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and Pfizer Inc for 158 Days on average.
| MGK | PFE | |
|---|---|---|
Market Cap | $33.70B | $158.56B |
Volume | 1,362,010 | 44,138,282 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $29.02 |
52-Week Low | $70.70 | $23.67 |
Typical Hold Time | 45 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Morningstar Mega Cap Growth ETF, trades at $94.42, down 0.53% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides exposure to large-cap U.S. growth stocks like Nvidia and Apple, with a low expense ratio of 0.05% (Vanguard, 2026-07-18). Recent news highlights its strong five-year returns and suitability for long-term growth investors.
The outlook for MGK is positive, driven by its concentrated mega-cap growth holdings and cost efficiency, though risks include tech sector volatility and market concentration. Analyst sentiment is favorable, emphasizing its role in growth portfolios for investors seeking higher returns with manageable risk.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
